Document is current
Any future updates will be listed below
-
Authors
Helliwell, Philip S https://orcid.org/0000-0002-4155-9105
Gladman, Dafna D https://orcid.org/0000-0002-9074-0592
Chakravarty, Soumya D
Kafka, Shelly
Karyekar, Chetan S
You, Yin
Campbell, Kim
Sweet, Kristen
Kavanaugh, Arthur
Gensler, Lianne S
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01009086 at ClinicalTrials.govnct01077362 at ClinicalTrials.govDocuments that mention this clinical trial
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
https://doi.org/10.1136/rmdopen-2019-001149
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)
https://doi.org/10.1136/annrheumdis-2015-209068
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
https://doi.org/10.1016/s0140-6736(13)60594-2
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
nct01009086 at ClinicalTrials.govDocuments that mention this clinical trial
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
https://doi.org/10.1136/rmdopen-2019-001149
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)
https://doi.org/10.1136/annrheumdis-2015-209068
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
nct01077362 at ClinicalTrials.govDocuments that mention this clinical trial
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
https://doi.org/10.1136/rmdopen-2019-001149
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)
https://doi.org/10.1136/annrheumdis-2015-209068
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
https://doi.org/10.1016/s0140-6736(13)60594-2
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Documents that mention this clinical trial
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
https://doi.org/10.1136/rmdopen-2019-001149
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)
https://doi.org/10.1136/annrheumdis-2015-209068
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
-
Funding
Funding for this research was provided by:
Janssen Research and Development
- License Information
